Software AG

  • WKN: A2GS40
  • ISIN: DE000A2GS401
  • Land: Germany

Nachricht vom 28.04.2015 | 19:49

Software AG to cancel treasury shares

Software AG  / Key word(s): Share Buyback/Corporate Action

28.04.2015 19:49

Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

Software AG (TecDAX, ISIN DE 0003304002 / SOW) today decided to cancel treasury shares, totaling a volume of 7,943,945 shares. The Management Board of Software AG has taken advantage of the authorization of the General Assembly of Software AG of May 3, 2013 and decided to redeem 7,943,945 treasury shares which had been acquired by the company through various buy-back authorizations with the effect of decreasing share capital. This corresponds to 9.14 percent of the share capital before redemption and capital decreases. The share capital of Software AG will amount after the redemption to EUR79,000,000.00 and will be divided into 79.0 million shares with a proportional amount of capital stock amounting to 1.00 EUR per share. The redemption is expected to be completed shortly. Management will handle questions in tomorrow's analyst conference call (Wednesday April 29, 2015, 9:00 am CEST). Darmstadt, 28 April 2015 Software Aktiengesellschaft The Management Board Software AG, Uhlandstr. 12, 64297 Darmstadt 28.04.2015 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at and
Language: English Company: Software AG Uhlandstraße 12 64297 Darmstadt Germany Phone: +49 (0)6151 92-1900 Fax: +49 (0)6151 92-34 1899 E-mail: Internet: ISIN: DE0003304002 WKN: 330400 Indices: TecDAX Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart End of Announcement DGAP News-Service

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

News im Fokus

Symrise verlängert Vorstandsvertrag von Dr. Heinz-Jürgen Bertram vorzeitig bis 2025

01. Dezember 2021, 15:38

Aktueller Webcast

Deutsche Konsum REIT-AG

FY 2020/2021 Financial Results

16. Dezember 2021

Aktuelle Research-Studie

Original-Research: GBC Insider Focus Index (von GBC AG): GBC Insider Focus Index

01. Dezember 2021